Clinical Trials on Unresectable or Metastatic Hepatocellular Carcinoma

Total 6537 results

University of Tennessee Cancer Institute
Wyeth is now a wholly owned subsidiary of Pfizer

Unknown

Temsirolimus as Second-line Therapy in HCC

Unresectable or Metastatic Hepatocellular Carcinoma

United States
MedImmune LLC

Completed

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (MEDI-573-1028)

Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditions

United States
BeiGene

Completed

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma

China
Akeso

Recruiting

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Unresectable, Non-metastatic Hepatocellular Carcinoma

China
Institut für Klinische Krebsforschung IKF GmbH...
Ipsen

Recruiting

Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Hepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular Carcinoma

Germany
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Centre Hospitalier Universitaire Dijon

Completed

Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study

Unresectable Non-metastatic Hepatocellular Carcinoma | Child A/B7 Cirrhosis

France
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Zhejiang University

Recruiting

A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors

Unresectable or Metastatic Advanced Solid Tumors

China
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
Incyte Corporation

Completed

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Unresectable or Metastatic Solid Tumors

United States
Hospital Sirio-Libanes

Completed

Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI

Primary or Metastatic Tumor in the Liver Parenchyma

Brazil
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Metastatic or Unresectable Solid Tumor Malignancy

United States
University Hospital, Caen

Unknown

Residual Plasma Concentration of Sorafenib and Adverse Events in CHC (PharmacoCHC)

Advanced or Metastatic Hepatocellular Carcinoma

France
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Metastatic or Locally Advanced Unresectable Solid Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network

Withdrawn

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Liver Cancer | HepatoCellular Carcinoma | Unresectable HepatoCellular Carcinoma

United States
Mayo Clinic

Recruiting

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8

United States
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

Unrectable or Locally Recurrent Hepatocellular Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Txinno Bioscience Inc.

Recruiting

A Study of TXN10128 in Subjects With Solid Tumors

Locally Advanced (Unresectable) or Metastatic Solid Tumors

Korea, Republic of
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Brazil, China, Colombia, Italy, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Thailand, United States, Argentina, France, Mexico, Turkey
Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
AstraZeneca

Recruiting

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Unresectable Hepatocellular Carcinoma

Japan
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, France, Korea, Republic of, China, Japan, Spain, Belgium, Croatia, Brazil, Austria, Italy, Costa Rica, Germany, Israel, Thailand, Turkey, Russian Federation, United Kingdom, Taiwan, Philippines, India, Chile, Finland, Greece, Sl... and more
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Unresectable Hepatocellular Carcinoma

United States
Guangzhou University of Chinese Medicine

Completed

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

Unresectable Hepatocellular Carcinoma

China
National Cancer Institute (NCI)

Completed

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma

United States
AstraZeneca

Approved for marketing

Himalaya Early Access Program

Unresectable Hepatocellular Carcinoma

United States
University of Miami
Surefire Medical, Inc.

Withdrawn

A Clinical Study of Precision TACE (P-TACE) With Surefire

Unresectable Hepatocellular Carcinoma

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Unresectable Hepatocellular Carcinoma

Belgium, Italy, United States, Germany, Canada
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors (CSG-1906-101)

Locally Advanced Unresectable or Metastatic Solid Tumors

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, China, Spain, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada

Clinical Trials on Unresectable or Metastatic Hepatocellular Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations